Article
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2005
Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba J L, Vieitez J M, Maeztu I, Sanchez J J, Queralt C, Mayo C, Mendez P, Moran T, Taron M
Abstract excerpt
BACKGROUND: North American and Japanese non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) activation via tyrosine kinase (TK) mutations respond dramatically to gefitinib treatment. To date, however, the frequency and effect of EGFR TK mutations have not been...
Topics
- Adult
- Aged
- Antineoplastic Agents
- Base Sequence
- Carcinoma, Non-Small-Cell Lung
- DNA Primers
- ErbB Receptors
- Female
- Gefitinib
- Humans